This “Cervical Cancer - Pipeline Insight, 2020” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Cervical Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
Global coverage
Cervical Cancer Understanding

Cervical Cancer: Overview

Cervical cancer starts in the cells lining the cervix -- the lower part of the uterus (womb). The cervix connects the body of the uterus (the upper part where a fetus grows) to the vagina (birth canal). Cancer starts when cells in the body begin to grow out of control. The cervix is made of two parts and is covered with two different types of cells.
The endocervix is the opening of the cervix that leads into the uterus. It is covered with glandular cells.
The exocervix (or ectocervix) is the outer part of the cervix that can be seen by the doctor during a speculum exam. It is covered in squamous cells.
The place where these two cell types meet in the cervix is called the transformation zone. The exact location of the transformation zone changes as you get older and if you give birth. Most cervical cancers begin in the cells in the transformation zone.

Symptoms

The most common symptoms of cervical cancer are:
bleeding between periods
bleeding after sexual intercourse
bleeding in post-menopausal women
discomfort during sexual intercourse
vaginal discharge with a strong odor
vaginal discharge tinged with blood
pelvic pain
Diagnosis

Diagnostic process may include the following tests:
A pelvic exam (which may include a rectal exam) - An examination in which health care professional checks the uterus, ovaries, and other organs near the cervix
Cystoscopy - A test in which the inside of the urethra and bladder are studied with a lighted device
Colonoscopy - A test in which the entire colon is examined with a slender, lighted instrument called a colonoscope
Treatment

Cervical cancer treatment options include surgery, radiotherapy, chemotherapy, or combinations of these. Deciding on the kind of treatment depends on several factors, such as the stage of the cancer, as well as age and overall state of health. Treatment for early-stage cervical cancer, when the cancer remains within the cervix, has a good success rate. The further a cancer spreads from its original area, the lower the success rate tends to be.

Cervical Cancer Emerging Drugs Chapters

This segment of the Cervical Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cervical Cancer Emerging Drugs

Z 100: Zeria

Zeria is conducting a phase III randomized, double-blind, placebo-controlled trial of Z-100 plus radiation therapy in patients with locally advanced cervical cancer. This study is a phase III, multicenter, double-blind, placebo-controlled, parallel group comparative study to evaluate the efficacy and safety of Z-100 with primary uterine cervical cancer on radiotherapy. The study will use a central randomization with a dynamic allocation using biased coin minimization.

Axalimogene filolisbac: Advaxis, Inc.

Axalimogene filolisbac is a type of cancer vaccine being developed as immunotherapy that attacks HPV-associated cancers such as cervical cancers. It works by alerting the body’s immune system to the presence of cancer, stimulating the body’s natural defenses to attack the cancer. Axalimogene filolisbac is given intravenously and is being developed for the treatment of persistent, recurrent, or metastatic, squamous or non-squamous cell cervical cancer in patients who progress beyond first-line therapy. If licensed, Axalimogene filolisbac will offer a new treatment option for this patient group.

Cervical Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Cervical Cancer drugs segregated based on following parameters that define the scope of the report.

Major Players in Cervical Cancer

There are approx. 50+ key companies which are developing the therapies for Cervical Cancer. The companies which have their Cervical Cancer drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, El Kendi Pharmaceuticals Manufacturing Company, Zeria Pharmaceutical, Advaxis, Biocad, AstraZeneca, Regeneron Pharmaceuticals, Sanofi, Shanghai Bovax Biotechnology Co., Ltd. etc.

Phases

This report covers around 50+ products under different phases of clinical development like
Mid-stage products (Phase II and Phase I/II)
Early-stage products (Phase I/II and Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Cervical Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Subcutaneous
Intravenous
Molecule Type
Products have been categorized under various Molecule types such as
Immunoglobulin Fc fragments
Monoclonal antibodies
Immunoglobulins
Immunoproteins
Serum globulins
Small molecules
Stem cell therapies
Immunotherapies
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cervical Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cervical Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cervical Cancer drugs.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Cervical Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Cervical Cancer.
September 2020: Agenus Presents Results from Two Large Cervical Cancer Trials at ESMO
160 patient balstilimab (PD-1) monotherapy trial achieves response rates of 14% in all treated patients and 19% in PD-L1 positive patients
155 patient balstilimab (PD-1) + zalifrelimab (CTLA-4) combination trial achieves response rates of 22% in all patients and 27% in PD-L1 positive patients
Cervical Cancer Report Insights
Cervical Cancer Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs
Cervical Cancer Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
How many companies are developing Cervical Cancer drugs?
How many Cervical Cancer drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cervical Cancer?
What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cervical Cancer therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Cervical Cancer and their status?
What are the key designations that have been granted to the emerging drugs?
Key Players
El Kendi Pharmaceuticals Manufacturing Company
Zeria Pharmaceutical
Advaxis
Biocad
AstraZeneca
Regeneron Pharmaceuticals
Sanofi
Shanghai Bovax Biotechnology Co., Ltd.
Key Products
Cemiplimab
BCD-100
Z-100
ADXS11-001
V501